N-Gene

About:

N-Gene is a clinical-stage bio-pharmaceutical drugs designed to focus on the development of proprietary synthetic small molecules.

Website: http://ngene.us/

Top Investors: Allos Therapeutics, Hiventures, Bankár

Description:

N-Gene is a developer of clinical-stage bio-pharmaceutical drugs designed to focus on the discovery, development, and commercialization of proprietary synthetic small molecules. The company's drugs use proprietary synthetic small molecule BGP-15 that has been found efficacious in various indications relating to adverse metabolic conditions, including type 2 diabetes mellitus by blocking JNK phosphorylation and has a new therapeutic effect via stress response modulation, enabling pharmaceutical companies to get a series of synthetic molecules to treat the insulin-resistance syndrome, improve cancer chemotherapy, and slow skin aging.

Total Funding Amount:

$3M

Headquarters Location:

Szentistván, Borsod-Abauj-Zemplen, Hungary

Founded Date:

1997-01-01

Founders:

Gabor Kalman

Number of Employees:

11-50

Last Funding Date:

2009-02-26

IPO Status:

Private

Industries:

© 2025 bioDAO.ai